Intradigm lands $18.5M to advance oncology treatment
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, and existing investors Alta Partners, Frazier Healthcare Ventures,… Continue Reading